Cost Plus Drugs

Mark Cuban Cost Plus Drug Company Teams Up with RxLink to Bring Pharmacy Cost Transparency to Patients of Leading Health Systems

Retrieved on: 
Mardi, mai 7, 2024
Prescription, SMS, Organization, Patient, Cost Plus Drugs, Pharmacy, PBC, Partnership, Pharmaceutical industry

DOVER, Del., May 7, 2024 /PRNewswire/ -- Today, RxLink, a firm founded with the same commitment to price transparency in prescription medicine as Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) announced a new collaboration to connect patients of leading health systems with Cost Plus Drugs' offering of safe medicines at the lowest possible price.

Key Points: 
  • Patients Automatically Receive Information on Pricing of Prescribed Medications, Including Cost Plus Drugs' Transparent Pricing
    DOVER, Del., May 7, 2024 /PRNewswire/ -- Today, RxLink, a firm founded with the same commitment to price transparency in prescription medicine as Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) announced a new collaboration to connect patients of leading health systems with Cost Plus Drugs' offering of safe medicines at the lowest possible price.
  • The MedMap™ now includes Cost Plus Drugs and has already identified and surfaced over $162,000 in patient savings after only 3 months of including Cost Plus Drugs pricing.
  • "We are excited to work with RxLink to bring lower prescription drug prices to consumers," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • "Cost Plus Drugs and RxLink share a common goal of providing consumers the lowest possible price for their prescription medication.

Mark Cuban Cost Plus Drug Company and Vivid Clear Rx Team Up to Increase Access to Low-Priced Prescriptions

Retrieved on: 
Lundi, avril 22, 2024
Professional Services, Health, Insurance, Human Resources, General Health, Pharmaceutical, Public, Pharmacy, Cost Plus Drugs, World Market (store), Prescription, Patient, Multimedia, PBC

The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) and Vivid Clear Rx, a pass-through pharmacy benefit manager, have teamed up to make it easy for patients to access low-cost prescriptions.

Key Points: 
  • The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) and Vivid Clear Rx, a pass-through pharmacy benefit manager, have teamed up to make it easy for patients to access low-cost prescriptions.
  • View the full release here: https://www.businesswire.com/news/home/20240422460983/en/
    Now, eligible Vivid Clear Rx members have direct access to purchase affordable prescriptions and have them shipped through Cost Plus Drugs using their pharmacy benefit plan.
  • By collaborating together, Cost Plus Drugs and Vivid Clear Rx aim to control drug costs for health plans and patients nationwide.
  • The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates.

Progressive Care Inc. Announces Record Full Year 2023 Results with Revenues of $49.7 Million, an Increase of 22% with Annual Gross Margins of 30%

Retrieved on: 
Jeudi, avril 11, 2024
Pharmacy, OTCQB, Cost Plus Drugs, OTC, PBM, Growth, Patient, Medicare, Bank statement, Successor, GAAP, Connect, Cryptocurrency

MIAMI, April 11, 2024 /PRNewswire/ -- Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care" or the "Company"), a personalized healthcare services and technology provider, today announced financial results for the year ended December 31, 2023. The Company reported record annual revenues of approximately $49.7 million, a 22% increase from results reported for the year ended December 31, 2022, driven by strong growth at its PharmcoRx pharmacies and the addition of multiple new 340B contracts in the second half of 2023.

Key Points: 
  • I am pleased with our team's success in greatly strengthening the Company's financial foundation and driving improved operational performance.
  • Sequentially, total revenues in the fourth quarter of 2023 increased by approximately 18% over revenue reported for the third quarter of 2023.
  • 340B contract revenue increased to approximately $9.0 million in 2023, an increase of approximately $5.2 million, or 136%, compared to approximately $3.8 million in 2022.
  • Fiscal 2023 results include a non-cash goodwill impairment charge of approximately $13.9 million, mostly related to the pharmacy services reporting unit.

Avanlee Care Inc. Makes Inc.'s 2024 Female Founders List

Retrieved on: 
Mercredi, avril 10, 2024
Family, Prescription, Caregiver, OTC, Woman, Ageing, Parent, Inc., Female, Cost Plus Drugs, Residential care

BILLINGS, Mont., April 10, 2024 /PRNewswire/ -- Inc. announced its seventh annual Female Founders list, honoring a bold group of 250 women whose innovations and ideas are shaping the world into a better place.

Key Points: 
  • BILLINGS, Mont., April 10, 2024 /PRNewswire/ -- Inc. announced its seventh annual Female Founders list, honoring a bold group of 250 women whose innovations and ideas are shaping the world into a better place.
  • Avanlee Christine, Founder and CEO of Avanlee Care Inc, said, "I'm thrilled to be part of this illustrious group of women.
  • Avanlee Care is an AI powered healthcare solution dedicated to making the lives of caregivers better.
  • The female founders on this year's list are a testament to what triumph over adversity looks like.

Price.com Announces Collaboration with Mark Cuban Cost Plus Drug Company to Make Prescription Drugs More Affordable

Retrieved on: 
Mardi, avril 2, 2024
Cost Plus Drugs, Partnership, Health, PBC, Pharmaceutical industry

LOS ANGELES, April 2, 2024 /PRNewswire/ -- In a significant step to improve healthcare affordability, Price.com has joined forces with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), marking a notable phase of transparency and ease of access in the prescription drug market.

Key Points: 
  • LOS ANGELES, April 2, 2024 /PRNewswire/ -- In a significant step to improve healthcare affordability, Price.com has joined forces with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), marking a notable phase of transparency and ease of access in the prescription drug market.
  • This joint effort aims to help consumers by providing a straightforward platform for comparing drug prices, making prescription medications more affordable.
  • "We are thrilled to collaborate with Price.com in our mission to make prescription drugs more affordable for consumers," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • "At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with Price.com, we are dedicated to providing affordable and accessible healthcare solutions for all."

Provell Pharmaceuticals and Mark Cuban Cost Plus Drug Company Bring Leading Hypothyroid Drug, Euthyrox®, to U.S. Patients at Low-Cost Prices through Direct-to-Consumer Model

Retrieved on: 
Mardi, mars 12, 2024
Health, Hypothyroidism, Entrepreneurship, Disease, Partnership, Patient, Pharmacy, Merck, HONEY, Doctor of Philosophy, MD, Insurance, Merck Group, PBC, Plasma protein binding, Cost Plus Drugs, Blister, Marketing, FDA, NTI, Physician, World Market (store), Medicine, Pharmaceutical industry

HONEY BROOK, Pa., March 12, 2024 /PRNewswire/ -- Provell Pharmaceuticals, a healthcare company that distributes world-class, branded drugs at generic prices by eliminating middlemen markups, today announced a partnership with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to offer patients direct access to a leading hypothyroid drug, Euthyrox®, at low-cost prices on the Cost Plus Drugs online platform.

Key Points: 
  • HONEY BROOK, Pa., March 12, 2024 /PRNewswire/ -- Provell Pharmaceuticals, a healthcare company that distributes world-class, branded drugs at generic prices by eliminating middlemen markups, today announced a partnership with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to offer patients direct access to a leading hypothyroid drug, Euthyrox®, at low-cost prices on the Cost Plus Drugs online platform.
  • It is now offered in the U.S. through Cost Plus Drugs and in retail pharmacies.
  • "By working directly with online platforms such as Cost Plus Drugs, which shares our vision to make drugs affordable and accessible to all, we are disrupting the traditional model and conferring significant savings to patients."
  • Currently, the U.S. healthcare system consists of complex pricing mechanisms, for both brand and generic medications, that artificially inflate prices.

Community Health Systems Partners With Mark Cuban Cost Plus Drug Company to Address the Rising Cost of Drugs and Potential Drug Shortages

Retrieved on: 
Jeudi, mars 7, 2024
Managed Care, Hospitals, Pharmaceutical, Health, CYH, Hospital, Cost Plus Drugs, Doctor of Philosophy, MD, Partnership, Food, CHS, Norepinephrine, World Market (store), Community Health Systems, Intensive care medicine, ERS, Patient, Adrenaline, Patient safety, Community, Pharmaceutical industry

Community Health Systems, Inc. (NYSE: CYH) (CHS) will become the first national healthcare system to purchase select pharmaceutical supplies from Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) as part of a new, collaborative relationship that promises to bring high-quality, lower cost drugs into the hospital setting.

Key Points: 
  • Community Health Systems, Inc. (NYSE: CYH) (CHS) will become the first national healthcare system to purchase select pharmaceutical supplies from Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) as part of a new, collaborative relationship that promises to bring high-quality, lower cost drugs into the hospital setting.
  • Drug shortages – Cost Plus Drugs is focused on manufacturing drugs that are often in limited supply, threatening patient treatment and outcomes when shortages occur.
  • CHS and Cost Plus Drugs are working together to identify, prepare for, and mitigate potential future drug shortages in the hospital setting.
  • “Community Health Systems has stepped forward to consider important issues related to drug supply, drug costs, patient care and outcomes,” said Alex Oshmyansky, MD, PhD, Chief Executive Officer of Mark Cuban Cost Plus Drug Company.

SmithRx and Mark Cuban Cost Plus Drug Company Announce $9.5 Million in Client Savings Through Innovative Autoimmune Drug Sourcing

Retrieved on: 
Lundi, mars 4, 2024
Supply Chain Management, Online Retail, Professional Services, Health, General Health, Pharmaceutical, Health Insurance, Infectious Diseases, Retail, Insurance, Human Resources, Pharmacy, Cost Plus Drugs, Silicon, Venrock, PBC, World Market (store), Public, Patient, PBM, Prescription, Pharmaceutical industry

SmithRx, a transparent and 100% pass-through PBM, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), announced today that in 6 months, they have saved SmithRx clients more than $9.5 million in the autoimmune category alone.

Key Points: 
  • SmithRx, a transparent and 100% pass-through PBM, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), announced today that in 6 months, they have saved SmithRx clients more than $9.5 million in the autoimmune category alone.
  • This milestone has been achieved by strategically sourcing the lowest net cost autoimmune medications, including impactful transitions to cost-effective alternatives through Cost Plus Drugs.
  • This successful alliance combines SmithRx's patient-first approach with Cost Plus Drugs’ revolutionary drug pricing strategy to tackle the highest cost drug category for many employers.
  • The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates.

SHARx and Mark Cuban Cost Plus Drug Company, PBC Join Forces to Save Underinsured Families Thousands of Dollars Per Year on High Cost and Specialty Medications

Retrieved on: 
Jeudi, février 22, 2024
Professional Services, Health, Insurance, Practice Management, Health Insurance, Pharmaceutical, Cost Plus Drugs, Catalog, Multimedia, PBC, Pharmaceutical industry

SHARx, one of the fastest-growing patient advocacy companies in the United States, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) announced today that they will be teaming up to address the High Cost and Specialty drug markets by offering underinsured members access to those medications at affordable prices.

Key Points: 
  • SHARx, one of the fastest-growing patient advocacy companies in the United States, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) announced today that they will be teaming up to address the High Cost and Specialty drug markets by offering underinsured members access to those medications at affordable prices.
  • The agreement expands SHARx’s extensive sourcing channels, opening the catalog of medications carried by Cost Plus Drugs to SHARx members.
  • View the full release here: https://www.businesswire.com/news/home/20240221055697/en/
    “High Cost and Specialty medications can cost upwards of $1.5 million per year in the United States,” said Corey Durbin, CEO of SHARx.
  • “At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with SHARx we are dedicated to providing affordable and accessible healthcare solutions for all."

Wheel Adds Three High-Impact Companies to Its Integrated Virtual Care Ecosystem, Delivering More Choice, Improved Access, and Affordability to Patients

Retrieved on: 
Jeudi, mars 7, 2024
Cost Plus Drugs, PBC, Health, Ecosystem, Organization, Patient, Nursing

AUSTIN, Texas, March 7, 2024 /PRNewswire/ -- Wheel, the virtual care platform powering the future of care, today announced it is adding three high-impact companies to its Integrated Virtual Care Ecosystem — Talkspace; Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs); and Health Gorilla. With these additions to the Wheel ecosystem, Wheel customers can easily connect patients with high-quality mental health services via Talkspace, provide transparent, affordable home delivery pharmacy options to patients via Cost Plus Drugs, and deliver seamless lab and diagnostic services with Health Gorilla.

Key Points: 
  • AUSTIN, Texas, March 7, 2024 /PRNewswire/ -- Wheel , the virtual care platform powering the future of care, today announced it is adding three high-impact companies to its Integrated Virtual Care Ecosystem — Talkspace; Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs); and Health Gorilla.
  • The Wheel Integrated Virtual Care Ecosystem extends Wheel's virtual care platform by bringing together best-in-class technologies, care networks, and solutions to provide everything customers need to stand up virtual care at scale.
  • With Wheel and Health Gorilla, patients and their care teams can seamlessly leverage all diagnostic results for fast and effective virtual care," said Steve Yaskin, CEO & Co-founder of Health Gorilla."
  • Wheel's Integrated Virtual Care Ecosystem is available to all Wheel customers who build their virtual care programs on the Wheel platform.